Search

Your search keyword '"Jacobs, Peter A."' showing total 18 results
Start Over Author "Jacobs, Peter A." Search Limiters Peer Reviewed Journal diabetes
18 results on '"Jacobs, Peter A."'

1. 241-OR: Increased Time in Range on Days with Structured Aerobic, Interval, or Resistance Exercise as Compared with Sedentary Days, in Adults with Type 1 Diabetes (T1D)

Author

LI, ZOEY, primary, RIDDELL, MICHAEL, additional, RICKELS, MICHAEL R., additional, BECK, ROY, additional, CASTLE, JESSICA R., additional, CLEMENTS, MARK A., additional, DOYLE, FRANCIS J., additional, GAL, ROBIN L., additional, GILLINGHAM, MELANIE B., additional, JACOBS, PETER G., additional, MARTIN, CORBY K., additional, PATTON, SUSANA R., additional, and CALHOUN, PETER, additional

Published
2022
Full Text
View/download PDF

2. 771-P: Acceptance of Decision Support Recommendations Improves Time in Range for People Living with Type 1 Diabetes on Multiple Daily Injections

Author

CASTLE, JESSICA R., primary, ESPINOZA, ALEJANDRO Z., additional, TYLER, NICHOLE S., additional, WILSON, LEAH M., additional, MOSQUERA-LOPEZ, CLARA M., additional, PINSONAULT, JOSEPH, additional, DODIER, ROBERT, additional, OGANESSIAN, SOS M., additional, BRANIGAN, DEBORAH, additional, GABO, VIRGINIA, additional, EOM, JAE H., additional, EL YOUSSEF, JOSEPH, additional, RAMSEY, KATRINA, additional, KUSHNER, TAISA, additional, WINTERS-STONE, KERRI, additional, CAFAZZO, JOSEPH A., additional, and JACOBS, PETER G., additional

Published
2022
Full Text
View/download PDF

3. 292-OR: Changes in Glycemia during Exercise Differ for Aerobic, Interval, and Resistance Workouts with No Impact of Insulin Delivery Modality for Adults with Type 1 Diabetes (T1D)

Author

RIDDELL, MICHAEL, primary, PATTON, SUSANA R., additional, MARTIN, CORBY K., additional, LI, ZOEY, additional, JACOBS, PETER G., additional, GILLINGHAM, MELANIE B., additional, GAL, ROBIN L., additional, DOYLE, FRANCIS J., additional, CLEMENTS, MARK A., additional, CALHOUN, PETER, additional, CASTLE, JESSICA R., additional, BECK, ROY, additional, and RICKELS, MICHAEL R., additional

Published
2022
Full Text
View/download PDF

4. 240-OR: Quantifying Glucose Utilization and Endogenous Glucose Production during Resistance Exercise in People with Type 1 Diabetes (T1D)

Author

YOUNG, GAVIN, primary, JACOBS, PETER G., additional, TYLER, NICHOLE S., additional, NGUYEN, THANH-TIN P., additional, CASTLE, JESSICA R., additional, WILSON, LEAH M., additional, BRANIGAN, DEBORAH, additional, GABO, VIRGINIA, additional, GUILLOT, FLORIAN H., additional, RIDDELL, MICHAEL, additional, and YOUSSEF, JOSEPH EL, additional

Published
2022
Full Text
View/download PDF

5. 291-OR: Using the Performance in Exercise and Knowledge (PEAK) Guidelines Incorporated in a Smartphone-Based Decision Support System Improves Glucose Outcomes during Free-Living Exercise

Author

WILSON, LEAH M., primary, JACOBS, PETER G., additional, GUILLOT, FLORIAN H., additional, TYLER, NICHOLE S., additional, KUSHNER, TAISA, additional, ESPINOZA, ALEJANDRO Z., additional, MOSQUERA-LOPEZ, CLARA M., additional, PINSONAULT, JOSEPH, additional, DODIER, ROBERT, additional, OGANESSIAN, SOS M., additional, BRANIGAN, DEBORAH, additional, GABO, VIRGINIA, additional, EOM, JAE H., additional, YOUSSEF, JOSEPH EL, additional, WINTERS-STONE, KERRI, additional, and CASTLE, JESSICA R., additional

Published
2022
Full Text
View/download PDF

6. 32-LB: Interstitial Glucose Levels during Exercise in Persons with and without Type 1 Diabetes

Author

RIDDELL, MICHAEL, primary, LI, ZHAOMIAN, additional, DSOUZA, NINOSCHKA, additional, YEUNG, CHRISTOPHER, additional, KESIBI, DURMALOUK, additional, PATTON, SUSANA R., additional, BECK, ROY, additional, JACOBS, PETER G., additional, CLEMENTS, MARK A., additional, GAL, ROBIN L., additional, DOYLE, FRANCIS J., additional, MARTIN, CORBY K., additional, CALHOUN, PETER, additional, SHERR, JENNIFER, additional, CASTLE, JESSICA R., additional, and RICKELS, MICHAEL R., additional

Published
2021
Full Text
View/download PDF

8. 694-P: Effect of Exercise on Sleep and Nocturnal Glucose in Type 1 Diabetes (T1D)

Author

JACOBS, PETER G., primary, LI, ZOEY, additional, CALHOUN, PETER, additional, GAL, ROBIN L., additional, BECK, ROY, additional, CASTLE, JESSICA R., additional, CLEMENTS, MARK A., additional, DASSAU, EYAL, additional, DOYLE, FRANCIS J., additional, GILLINGHAM, MELANIE B., additional, MARTIN, CORBY K., additional, RICKELS, MICHAEL R., additional, PATTON, SUSANA R., additional, and RIDDELL, MICHAEL, additional

Published
2020
Full Text
View/download PDF

9. 687-P: Support Vector Regression Model Predicts Glucose Changes during Exercise in Type 1 Diabetes

Author

YOUNG, GAVIN, primary, LI, ZOEY, additional, CALHOUN, PETER, additional, GAL, ROBIN L., additional, BECK, ROY, additional, CASTLE, JESSICA R., additional, CLEMENTS, MARK A., additional, DASSAU, EYAL, additional, DOYLE, FRANCIS J., additional, GILLINGHAM, MELANIE B., additional, MARTIN, CORBY K., additional, RICKELS, MICHAEL R., additional, PATTON, SUSANA R., additional, RIDDELL, MICHAEL, additional, and JACOBS, PETER G., additional

Published
2020
Full Text
View/download PDF

10. 1051-P: Improving Glycemic Outcomes in T1D Using an Automated Decision Support Recommender System: Evaluation In Silico and Compared with Physician Recommendations

Author

TYLER, NICHOLE S., primary, MOSQUERA-LOPEZ, CLARA M., additional, WILSON, LEAH M., additional, RESALAT, NAVID, additional, DODIER, ROBERT, additional, BRANIGAN, DEBORAH, additional, GABO, VIRGINIA, additional, YOUSSEF, JOSEPH EL, additional, CASTLE, JESSICA R., additional, and JACOBS, PETER G., additional

Published
2019
Full Text
View/download PDF

12. 741-P: More Time-in-Range during Days with Structured Exercise vs. Sedentary Days in Adults with Type 1 Diabetes

Author

RIDDELL, MICHAEL, primary, LI, ZOEY, additional, BECK, ROY, additional, GAL, ROBIN L., additional, JACOBS, PETER G., additional, CASTLE, JESSICA R., additional, GILLINGHAM, MELANIE B., additional, CLEMENTS, MARK A., additional, PATTON, SUSANA R., additional, DASSAU, EYAL, additional, DOYLE, FRANCIS J., additional, MARTIN, CORBY K., additional, CALHOUN, PETER, additional, and RICKELS, MICHAEL R., additional

Published
2019
Full Text
View/download PDF

13. 1038-P: Results of Interim Analysis of a Randomized Crossover Study in Type 1 Diabetes (T1D) of a Dual-Hormone Closed-Loop System with Xerisol™ Glucagon vs. Insulin-Only Closed-Loop System vs. a Predictive Low Glucose Suspend System

Author

WILSON, LEAH M., primary, JACOBS, PETER G., additional, RESALAT, NAVID, additional, REDDY, RAVI, additional, YOUSSEF, JOSEPH EL, additional, BRANIGAN, DEBORAH, additional, LEITSCHUH, JOSEPH A., additional, SENF, BRIAN, additional, GABO, VIRGINIA, additional, and CASTLE, JESSICA R., additional

Published
2019
Full Text
View/download PDF

17. 1038-P: Results of Interim Analysis of a Randomized Crossover Study in Type 1 Diabetes (T1D) of a Dual-Hormone Closed-Loop System with Xerisol™ Glucagon vs. Insulin-Only Closed-Loop System vs. a Predictive Low Glucose Suspend System.

Author

WILSON, LEAH M., JACOBS, PETER G., RESALAT, NAVID, REDDY, RAVI, YOUSSEF, JOSEPH EL, BRANIGAN, DEBORAH, LEITSCHUH, JOSEPH A., SENF, BRIAN, GABO, VIRGINIA, and CASTLE, JESSICA R.

Abstract

Dual-hormone systems show promise to reduce hypoglycemia, but require a stable liquid glucagon formulation. XeriSol™ glucagon is a shelf-stable glucagon product for this use. Nineteen subjects with T1D are completing a single-center three-day outpatient study comparing control modes of the Oregon Artificial Pancreas system: 1) dual hormone (DH) closed-loop with Novolog™ insulin and XeriSol™ glucagon, 2) insulin-only single hormone (SH) closed-loop, 3) insulin-only predictive low glucose suspend system (PLGS). In clinic aerobic exercise (45 minutes at 60% VO2max) and home exercise was completed with each arm. SH and DH used automated exercise detection to adaptively dose insulin/glucagon for predicted hypoglycemia and tailored mealtime dosing based on past meal responses with an adaptive algorithm. An interim analysis after 7 subjects was completed for safety. The primary outcome measures are % time 70-180 mg/dL and % time <70 mg/dL for the 3-day study and the 4-hour period from start of exercise until the next meal. From start of exercise until the next meal, DH showed a clinically meaningful reduction of time in hypoglycemia compared with PLGS and SH. For the entire study, DH showed a clinically meaningful lower time <70mg/dL. No serious events or unexpected side effects occurred. Disclosure: L.M. Wilson: None. P.G. Jacobs: Stock/Shareholder; Self; Pacific Diabetes Technologies. N. Resalat: None. R. Reddy: None. J. El Youssef: None. D. Branigan: None. J.A. Leitschuh: Other Relationship; Self; AgaMatrix. B. Senf: None. V. Gabo: None. J.R. Castle: Advisory Panel; Self; Novo Nordisk Inc., Zealand Pharma A/S. Consultant; Self; Dexcom, Inc. Research Support; Self; Dexcom, Inc., Xeris Pharmaceuticals, Inc. Funding: JDRF [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

18. 333-OR: Assessing Mealtime Macronutrient Content: Patient Perceptions vs. Expert Analyses via a Novel Phone App.

Author

GILLINGHAM, MELANIE B., MARTIN, CORBY K., PATTON, SUSANA R., LI, ZOEY, JACOBS, PETER G., RIDDELL, MICHAEL, RICKELS, MICHAEL R., CASTLE, JESSICA R., CLEMENTS, MARK A., DASSAU, EYAL, DOYLE III, FRANCIS J., CALHOUN, PETER, GAL, ROBIN L., and BECK, ROY

Abstract

People with type 1 diabetes (T1D) estimate the carbohydrate (CHO) content of meals to enable accurate insulin dosing, yet protein and fat content of meals also influences post-prandial glycemia. As part of an observational study examining the impact of exercise and nutrient consumption on glycemia, we examined accuracy in estimating macronutrient content of free-living meals via a novel phone app. Participant estimates of nutrient content were compared to expert nutrition analyses performed via the Remote Food Photography Method (RFPM). We report results from 30 of 33 randomized with analyzable food photos. Participants were 15-65 years (32±14 years); 27% identified as female. Participants were asked to take photos before and after meals/snacks on up to 16 days over a 28-day period, enter CHO estimates and estimate if meals were low (<13%), typical (13-<18%), or high (≥18%) protein and if meals were low (<26%), medium (26-<32%), or high (≥32%) fat. The phone app plus RFPM captured 92±27% of estimated energy needs. Of 1,292 food photos analyzed, 429 contained < 25 g (small), 641 contained 25-75 g (medium), and 222 contained > 75 g (large) amounts of CHO. Participants estimated CHO in small or medium meals within 10 g of the expert analyses. They were less accurate estimating CHO for larger meals (-56 ± 46 g). Likewise, most correctly categorized low and typical protein (63%, 50%) as well as low and typical fat (62%, 67%) meals. Few correctly categorized meals high in protein (17%) or fat (16%). Participants' estimation accuracy for larger meals did not differ by T1D duration. The phone app successfully collected individuals' food intake and estimated macronutrient intake, but showed that participants consistently underestimated nutrient intake for large meals. Accurate estimation of total macronutrients in meals could be leveraged to improve insulin decision support tools and closed loop systems; development of tools to improve macronutrient estimation skills should be considered. Disclosure: M.B. Gillingham: None. C.K. Martin: Advisory Panel; Self; EHE. Consultant; Self; ACAP Health, Florida Hospital, WW, Zafgen, Inc. Other Relationship; Self; Academy of Nutrition and Dietetics. S.R. Patton: None. Z. Li: None. P.G. Jacobs: Stock/Shareholder; Self; Pacific Diabetes Technologies. M. Riddell: Advisory Panel; Self; Xeris Pharmaceuticals, Inc. Research Support; Self; Dexcom, Inc. Speaker's Bureau; Self; Insulet Corporation, Medtronic MiniMed, Inc. Stock/Shareholder; Self; Zucara Therapeutics Inc. M.R. Rickels: None. J.R. Castle: Advisory Panel; Self; Novo Nordisk Inc., Zealand Pharma A/S. Consultant; Self; Dexcom, Inc. Research Support; Self; Dexcom, Inc., Xeris Pharmaceuticals, Inc. M.A. Clements: Advisory Panel; Self; Glooko, Inc. Consultant; Self; Eli Lilly and Company. Speaker's Bureau; Self; Medtronic. E. Dassau: Consultant; Self; Eli Lilly and Company, Insulet Corporation. Research Support; Self; Dexcom, Inc., DreaMed Diabetes, Ltd., Insulet Corporation, Roche Diabetes Care, Tandem Diabetes Care, Xeris Pharmaceuticals, Inc. Speaker's Bureau; Self; Roche Diabetes Care. Other Relationship; Self; ModAGC. F.J. Doyle: Consultant; Self; ModeAGC. Other Relationship; Self; Insulet Corporation. P. Calhoun: Stock/Shareholder; Self; Dexcom, Inc. R.L. Gal: None. R. Beck: Other Relationship; Self; Abbott Laboratories, Ascensia Diabetes Care, Bigfoot Biomedical, Dexcom, Inc., Insulet Corporation, Lilly Diabetes, Roche Diabetes Care, Tandem Diabetes Care. Funding: The Leona M. and Harry B. Helmsley Charitable Trust [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results